Arctic Bioscience holdt presentasjon på Facebook/Xtrainvestor idag, som er tilgjengelig på InQrate:
2 Likes
Noen som snuser på denne? Også en aksje som bare faller og faller, hva er cash-beholdningen og hva er bokført egenkapital her, rundt 300 mill?
6.8.2021, 07:30 · Cision
Arctic Bioscience AS: Arctic Bioscience H1 2021 results: phase IIb study on track and revenue up 50% y/y
Arctic Bioscience AS (“Arctic Bioscience” or “the company”) today announces its results for the first half 2021.
Highlights
-
Successful private placement and IPO raising NOK 300 million, with first day of trading on Euronext Growth on 24 February 2021
-
On track and on budget for phase IIb clinical study on HRO350 in mild-to-moderate psoriasis, planned start H1 2022
-
Financial strength to execute on ongoing development programs, invest in new production facility and capacity to participate in new selected pre-clinical trials
-
Revenue increased 50% y/y driven by increased B2B sales in Europe and the US
-
EBITDA of NOK -19.9 million, impacted by NOK 8.8 million of non-recurring costs, mainly related to the IPO
-
Completed basic design for new production facility confirming 150 metric tons of capacity for nutraceutical and pharmaceutical products to be available H2 2023.
-
Announced collaboration with Smerud Medical Research International to develop new drug candidate for normal brain development in extremely premature infants
Financials
(NOK million) 1H 2021 1H 2020 2020
Revenues 12.0 8.0 20.6
Gross profit 3.4 2.8 6.1
Adjusted gross profit* 4.0 2.8 6.1
EBITDA -19.9 -9.5 -20.5
Adjusted EBITDA** -11.2 -9.5 -20.5
Net investing cash flow -22.6 -1.2 -1.3
Cash holdings 258.7 11.5 12.6
- Adjustments to cost of sales are related to non-recurring costs associated with a change in distributor relationship in the USA.
** Adjustments to operating expenditures are made for costs associated with the listing on Euronext Growth
Review
Arctic Bioscience has two businesses, pharmaceutical and nutraceutical, which are built upon a single proprietary technology and knowledge platform.
Arctic Bioscience’s pharmaceutical business is in the process of developing a drug candidate (HRO350) - a novel oral treatment for mild-to-moderate psoriasis. There is significant unmet medical need for new treatment options for the mild-to-moderate category as well as a large market opportunity. Arctic Bioscience has shown promising results in a pilot clinical trial on HRO, and a large, randomized phase IIb study is scheduled to be initiated in H1 2022.
During the first half, the HRO350 development program continued on timeline and on budget. Site feasibility for the phase IIb study was initiated in Q2 and is due to be completed in Q4 2021. The company also received a grant of NOK 4.8 million from The Research Council of Norway to study the mechanism of action for HRO350. Additionally, the company announced a collaboration with Smerud Medical Research International to develop a new drug candidate for extremely premature infants based on the same technology platform.
Arctic Bioscience’s nutraceuticals business sells premium Omega 3 products via B2B and B2C channels globally and B2B2C in China through a strategic sales partnership with Kotler Marketing Group. The company experienced continued growth of 50% y/y in the first half 2021 compared with H1 2020, driven by an increase in B2B bulk oil sales to the Americas and Europe. Adjusted gross profit was NOK 4.0 million. China is an important market for the company and the first half saw the foundation for market entry and efficient growth established, with three products (Romega Prenatal, Romega Eye Health and Romega Brain Health) deployed via multiple e-commerce platforms in China.
In February, Arctic Bioscience completed a private placement raising NOK 300 million. The proceeds from the transaction will be used to invest in the development of the Company’s novel treatment against mild-to-moderate psoriasis and to invest in a new state-of-the-art production and process facility. The proceeds will also contribute to strengthen the company’s financial capacity and ability to participate in new selected pre-clinical trials.
On a consolidated level, adjusted EBITDA margin improved from -120% in H1 2020 to -93% in H1 2021. Total cash flow from investments to further the company’s growth plan totaled negative NOK 22.6 million in the first half. The company’s financial position at the end of the period was strong, with cash and cash equivalents amounting to NOK 259 million.
Commenting on developments, CEO Ole Arne Eiksund said:
“Operationally and financially, the first half year of 2021 has been an eventful one for Arctic Bioscience. The most important message is that the phase IIb study for our drug candidate HRO 350 targeting mild-to-moderate psoriasis remains on track. We are also well on our way with the state-of-the-art production facility in Ørsta, which we expect to significantly improve company gross margins and profitability. Revenues from our nutraceutical business were up strongly and we expect further growth in the second half of the year. Combined with financial support from our shareholders, we are in a good position to develop the company further.”
Outlook
Arctic Bioscience is progressing well in all business areas and remains positioned to capitalize on the unique properties of herring roe to deliver both pharmaceutical and nutraceutical products to the global population.
During the second half of 2021, the main priority for the pharma business is to continue feasibility and secure sites for the HRO350 phase IIb clinical trial, and to initiate the research collaboration for development of the novel drug candidate for extremely premature infants. The Nutra business will focus on entering new geographies, and the new product Romega Brain will be launched - which is expected to increase B2C revenue. In addition, the company will initiate construction work related to the building of the factory at the company’s premises in Ørsta.
Financially, the company aims for full year 2021 revenue growth of 40%+ and an EBITDA margin in the -95% to -70% range. Total investments related to the HRO 350 development for the full year is estimated to NOK 40 to 50 million.
Results Presentation
CEO Ole Arne Eiksund and CFO Danielle Glenn will present the H1 2021 results by webcast today, Thursday August 26th, at 08:30 CEST.
The presentation and subsequent Q&A will be held in English.
The presentation can be accessed with the following link:
https://streams.eventcdn.net/arcticbioscienceas/financial-results-first-half-2021/register
For more information, please contact
Ole Arne Eiksund
CEO Arctic Bioscience
Phone: +47 908 43 944
Danielle Glenn
CFO Arctic Bioscience
Phone: +47 909 98 201
About Arctic Bioscience
Arctic Bioscience is a biotech company developing pharmaceutical and nutraceutical products based on the unique properties of herring roe oil, composed of complex bioactive marine compounds, including lipids essential to maintaining cell membranes. The nutraceutical products contain lipids which contribute to the normal functioning of brain, heart and vision.
The company is developing a novel drug candidate (HRO350) for mild-to-moderate psoriasis, a large global patient population where there is substantial need for effective, convenient and cost-effective new medicines with beneficial safety profiles. Nutraceuticals from Arctic Bioscience are sold worldwide as bulk ingredients to other companies making dietary supplements (B2B) and as finished goods under the ROMEGA™ brand (B2C), with significant expansion potential all channels and regions.
To support its long-term growth strategy, Arctic Bioscience is planning a state-of-the-art manufacturing facility in Ørsta. Easy access to the raw material and proprietary production processes will increase control of the value chain, improve margins and enable large-scale, high-quality manufacturing.
Arctic Bioscience is led by a highly competent team with significant expertise developing marine oils and extensive experience from some of the world’s leading pharmaceutical, technology and financial services companies.
16.11.2021, 08:05 · Cision
Arctic Bioscience AS: Arctic Bioscience - Strengthening IP platform with new patent for method for utilizing immature herring roe
Arctic Bioscience, a biotech company with a pre-commercial pharmaceutical business and a commercial nutraceutical business, is pleased to announce it is granted a U.S. patent[1 ]with a new method related to type II diabetes. The patent claims protection for a method utilizing a lipid composition with a phospholipid extract from immature herring roe. The method is based on the same patented technology that is being used in the company’s two ongoing development programs for psoriasis and brain development.
“Arctic Biosciences pharmaceutical development programs are based on the company’s proprietary technology utilizing a lipid composition with a phospholipid extract from immature herring roe. Building a portfolio of patents for various utilizations of our technology and methods is an important part of our strategy to strengthen our IP platform to safeguard ongoing development programs for existing and new drug candidates.” says CEO Ole Arne Eiksund.
Arctic Bioscience’s drug candidate for treatment of mild-to-moderate psoriasis, HRO350, contains substances with the potential to affect cellular processes, with anecdotal evidence supporting relevance in inflammatory conditions. As such, market potential for our platform technology is significant, potentially opening large addressable markets.
In addition to protecting ongoing and future development programs, securing exclusive rights for utilisation of the technology in core and adjacent areas may represent opportunities for new business areas for Arctic Bioscience in the future. Diabetes type II is a major global health challenge.
Going forward, Arctic Bioscience’s focus will remain on the upcoming phase II study for psoriasis where the unmet need continues to be high and the market opportunity attractive. The company has also an ongoing collaboration with Smerud Medical Research to develop a new novel drug candidate for brain development in extremely premature infants, also based on our existing technology platform.
For more information, please contact
Ole Arne Eiksund
CEO Arctic Bioscience
Phone: +47 908 43 944
Danielle Glenn
CFO Arctic Bioscience
Phone: +47 909 98 201
About Arctic Bioscience
Arctic Bioscience is a biotech company developing and commercializing nutraceutical products based on herring roe oil. Herring roe oil contains lipids that are essential to maintain cell membranes, contributing to normal functioning of brain, heart, and vision. Nutraceuticals from Arctic Bioscience are sold globally as bulk ingredients to other companies making dietary supplements, and as finished goods under the Romega brand. The strategy is to switch sales from bulk to finished goods and focus markets are USA and China.
The company is developing HRO350 - a novel investigational drug candidate with herring roe as raw material. HRO350 is being developed for treatment of mild-to-moderate psoriasis. This is a large patient group in need of new effective medicines with beneficial safety profile. Arctic Bioscience is led by a team of highly competent people with experience in developing marine oils and experience from global pharmaceutical companies.
Reference:
- U.S. patent number 11,135,230B2
Spennende selskap som jeg vil anbefale å ta en nærmere kikk på!
På TV2 nyhetene i går: Silderogn skal hjelpe prematurfødte barn
Arctic Bioscience Q3 2021 Operational Update | live
2 Likes
1 Like
Enda en positiv artikkel om ABS:
1 Like
Anbefaler flere å se denne presentasjonen, spennende selskap med store muligheter for snarlig gjennombrudd!
Arctic Bioscience (ABS) - oppstart av medisinfabrikk:
Arctic Bioscience – ticker ABS – starter nå byggingen av fabrikk for produksjon av ekstrakter fra silderogn for kosttilskudd og legemidler og fikk i den forbindelse stor oppmerksomhet på bl.a. TV2 og NRK. Arctic Bioscience selger i dag sine ekstrakt som omega-3 kosttilskudd under produktnavn Romega med salg i Europa, USA og Asia. Selskapet har gjennomført pilotstudie for bruk av ekstrakt som legemiddel til behandling av psoriasis med gode resultater og en større internasjonal fase IIb studie skal igangsettes i 2022. Selskapet er videre i gang med utvikling av legemiddel til hjelp for hjerneutviklingen på ekstremt premature barn. Selskapets to områder deler en proprietær teknologi og IP-plattform med flere patenter der man så sent som i midten av november fikk patent på en metode for bruk av ekstrakter fra silderogn innen diabetes. Selskapets toppledelse har bakgrunn fra større internasjonale legemiddelselskap. På torsdag, 25.november, kl 1030 kommer CEO Ole Arne Eiksund, CFO Danielle Glenn og Medical Director Runhild Gammelsæter til Xtrainvestor for å fortelle om fabrikken, dagens virksomhet og planene fremover. Du kan se sendingen live eller i opptak på inQrate eller Xtrainvestors Facebook-side. Hvis du vil at selskapet skal svare på spørsmål kan du sende de til info@xtrainvestor.com
Ble presentert på TV2 nyhetene 17 nov
Bygger ny fabrikk før de endelige resultatene er klare, hva tenker du at det kan tyde på?
Usikkert produkt og lite tro på egen fremtid?
Jeg vil ikke anbefale noen å handle, men anbefaler å se nærmere på selskapet og vurdere om fremtiden ser lovende ut. Når denne blir kjent og anbefalt i media kjøpes den ikke på dagens kurser.
Har selv for første gang handlet en liten post på dagens dupp, vil sannsynligvis kjøpe mer til uken.
Ser Dnb setter 4X på denne med oppdatering i dag, noen som har tanker rundt dette? Har ikke fulgt selskapet tidligere, men etter det jeg leser bør dette være vinn vinn? Eller skal de legge til rette for emi?
Finnes faktisk en tråd for selskapet fra gammelt av. 
Jeg syntes selskapet så veldig lovende ut før, men er litt redd for at konkurransen på psoriasis har blitt veldig mye vanskeligere de siste få årene.
Aksjen har flatet ut, så en fin base akkurat nå
1 Like
Off.
Ikke nødvendigvis spikeren i kista, men ser ikke så bra ut.
Arctic Bioscience - Announces top-line results from the phase 2b HeROPA study
All patients have passed 6 months of treatment in the HeROPA phase 2b clinical
study, which compared HRO350 to placebo. While the high dose active treatment
arm showed an effect close to the assumed effect level, the placebo rate was
unexpectedly high, preventing the achievement of the primary end-point. The
HeROPA study is still ongoing and placebo controlled for 52 weeks.
“We have strong confidence in our phospholipid-based technology platform for
resolving inflammation. The study is still ongoing, and the promising effects
observed in the treatment arm at the 6-month read-out are encouraging. This is a
52-week trial, and based on prior clinical studies, we know that HRO350 has time
to onset of effect”, says CEO Christer L. Valderhaug.
Arctic Bioscience will continue investigating the data in collaboration with its
Contract Research Organization (Smerud Medical Research International) to
identify the reasons behind the unexpectedly high placebo rate. Mild-to-moderate
psoriasis is a fluctuating disease where patients can experience spontaneous
improvements, and the disease is often less severe during the summer, due to
sunlight exposure. Thus, endpoints analyzed after 52 weeks of treatment may
elucidate how disease fluctuation over a full year may have impacted the 26-week
primary endpoint. Of note, there have been no safety concerns, and no unexpected
serious events related to the study medication have been reported to date.
“We will investigate deeper into the data from the 6-month read-out, while the
study proceeds with 12-months of treatment. Our aim is to provide an oral
treatment option for patients, and to that end we have carefully and pro
-actively explored alternative regulatory and go-to-market strategies, which we
will assess as new insights emerge. The data shows potential, and once we have
completed more detailed analyses, we will decide on the course we believe offers
the greatest potential moving forward”, says CEO Christer L. Valderhaug.
PASI50 (50% improvement in PASI score) was chosen as primary endpoint to align
with regulatory guidelines on clinical studies in psoriasis. The study is still
ongoing, thus numeric data are not disclosed at this time.
“The high placebo rate in this trial was surprising and warrants further
investigation. Data from our previous study showed a statistically significant
improvement over placebo in the same patient population, and we also have
cellular studies showing anti-inflammatory effects of HRO350 with relevance in
psoriasis. We are grateful to the patients and investigators participating in
the HeROPA trial, and hope that 52-week data may provide further answers on
effect rate versus placebo and document safety”, says Medical Director Runhild
Gammelsæter.
Arctic Bioscience will continue the global market expansion of its nutraceutical
pipeline where we see a significant growth potential. The company will also
perform a full strategic and organizational assessment to secure a sustainable
financial platform. Cash preservation initiatives will be put in place to ensure
that available financial resources enable the company to complete the 12-month
study and continue product development, regardless of the strategic direction
taken.
CEO Christer Valderhaug and Medical Director Runhild Gammelsæter, will present
the findings of the study and the next steps during a webcast on Wednesday,
October 16th, at 12:00 CET. A separate invitation will be published at Newsweb.
This information is considered to be inside information pursuant to the EU
Market Abuse Regulation and is subject to the disclosure requirements pursuant
to Section 5-12 in the Norwegian Securities Trading Act. This stock exchange
announcement was published by Jone R. Slinning, CFO at Arctic Bioscience AS, on
the date and time as set out above.
For further information, please contact:
Christer L. Valderhaug
Placebogruppen må ha solet seg mye i sommer.
1 min
Eivind Bøe
DEL
Det Euronext Growth-noterte bioteknologiselskapet melder om resultater fra en studie som sammenligner legemiddelkandidaten deres med placebo.
Resultatene viser at placebo-raten var uventet høy, og det hindret at det primære målet for studien ble nådd.
Alle pasientene har gått gjennom seks måneders behandling, men studien pågår fortsatt.
Selskapet vil undersøke videre hva som kan være grunnen til den uventede høye placebo-raten.
Nå vil selskapet gjøre en full strategisk og organisasjonsmessig gjennomgang for å sikre en bærekraftig finansiell plattform.
Selskapet vil ta grep for å bevare kontanter, noe som skal sikre at studien kan gjennomføres, uavhengig av hvilken strategisk retning som tas.
Arctic Bioscience forsøker å lage et psoriasis-medikament.
Markedsverdien er 330 millioner kroner etter en aksjeoppgang på 45 prosent det siste året, ifølge Infront.
Eller har corona vaksinen kurert psoriasis 
Med tanke på at psoriasis har en sterk psykologisk trigger, så er det naturlig å anta at man får en ekstra sterk placebo-effekt muligens?
En 6 måneders avlesning som inkluderer sommerhalvåret hvor psoriasis nesten alltid blir bedre er nok et moment.
Spent på hva de sier i morgen.